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Abstract. In a community in Kwale district, Kenya, selective mass chemotherapy with
metrifonate caused a marked reduction in the intensity of Schistosoma haematobium
infection from 46.5 to 9.4 eggs/hr and a sharp fall in prevalence of gross hematuria from
18.3% to 5. 1%, although overall prevalence was reduced only slightly from 67.4% to 54%.
The effect of metrifonate on cure rate and reduction of infection intensity was limited by
both age and pretreatment infection intensity. Rate of improvement from gross hematuria
was similar in all ages and in all classes of intensity of infection. Two doses of metrifonate
reduced the prevalence of gross hematuria as much as 3 doses did, while the effect of a
single dose on morbidity remains to be clarified.
Chemotherapy is playing an increasing role in
the control of schistosomiasis and also acts di
rectly as a disease control agent.' Thus, the as
sessment ofcontrol programs should include the
impact on morbidity.2
Metrifonate has been used in selective mass
chemotherapy programs for urinary schistoso
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miasis because it is effective, inexpensive, and
has few side effects. â€T̃his study was designed to
assess its effectiveness against Schistosoma hae
matobium infection at the community level by
using quantitative parasitological techniques and
by assessing gross hematuria. We also describe
the effectiveness of single and double doses of
metrifonate on cure rate, reduction of infection
intensity, and prevalence of gross hematuria.
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Study area and population
The study was conducted in Kenya at Mwa
chinga village, Kwale district, an area known to
be highly endemic for urinary schistosomiasis.3
The number of residents registered at the 1982
census was 1,338 (617 males and 721 females).
About half of the people were under 15 years of
age.
Urine examination
Pretreatment urine examination was done in
December 1983. Urine was collected 1 hr after
the previous urination during mid-day. The in
tensity of infection was expressed as the number
of eggs excreted per 1 hr assessed by the filtration
method of Peters.4 The rationale for this method
has been published elsewhere.5 The geometric
mean was obtained by using the n + 1 transfor
mation for a series of egg outputs including zeros.
The appearance of urine was classified as yellow,
brown (bloody), or red (very bloody). Bloody
urine was used as a morbidity indicator, because
it is a simple, specific, and sensitive indicator of
infection.6
Selective mass chemotherapy
Treatment was given in February and March
1984 and effectiveness was evaluated 4 months
later. Subjects passing eggs at least once in 4
previous examinations (June and December
1982, June and December 1983) and all children
5â€”15years old were treated. Metrifonate was
scheduled to be given 3 times at a dose of 7.5
mg/kg body weight at 2-week intervals.7
RESULTS
Post-treatment prevalence and intensity of
inftction, and frequency of gross hematuria
Urine specimens of 677 villagers were exam
ined. Prevalence and intensity of infection and
frequency of hematuria showed similar patterns
ofvariancewithage,allincreasingrapidlytothe
10â€”14year group, followed by a steady decline
in adults(Table 1).Overallprevalenceof he
maturia was 18.3%, with 5% (34/677) having
very bloody urine.
Out of 813 subjects qualifying for treatment,
690 took metrifonate: in a single dose (n = 118),
2 doses (n = 159), and 3 doses (n = 413).
Four months later, 726 villagers were exam
ined for eggs and urine color. The results are
TABLE3








































Cure rates of children were significantly less than those of adultsin each levelof intensity of infection (P < 005. x2 statistic).
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TABLE 6
Reduction in intensity ofinfrction ofpatients receiving
3 doses of metrifonate








subjects with hematuria in this group was very
small (Table 3).
Cure rate in relation to sex, age, and
intensity of infection
Table 4 shows the cure rate among subjects
receiving 3 doses of metrifonate. Cure rate was
not influenced by sex, but varied with age and
intensity ofinfection, being significantly lower in
children (<14 years) than in adults (>14 years)
(P < 0.001). Those with lower egg counts had a
higher cure rate than those with initially higher
egg counts (P < 0.001).
Table 5 compares the cure rate of children and
adults who had the same level of infection in
tensity. At higher levels of infection, metrifonate
was still less effective in children than adults (P <
0.05, x2 statistic).
Reduction of egg output in relation to sex, age,
and intensity of infection
Table 6 shows the geometric mean of egg count
among subjects who completed 3 doses of me
trifonate. Sex did not affect reduction in egg count,
TABLE 4
Parasitological cure rate of patients given 3 doses of
metrzfonate at 7.5 mg/kg body weight by sex, age,











shown in Table 1. Mass chemotherapy caused a
sharp fall in the intensity of infection, though the
overallprevalencewas only slightlyreduced.
Prevalence of hematuria was reduced to less than
one third of the pretreatment level, and red urine
was observed in only 0.8% of the specimens.
Cure rate, reduction in egg output, and gross he
maturia in relation to dosage
Among those treated with metrifonate, 336
individualsunderwentbothpre-and post-treat
ment urine examinations (7 samples were not
examined for color due to an oversight). Results
are shown in Tables 2 and 3. The cure rate and
percent reduction of mean egg output were sig
nificantly lower in the groups with fewer doses
(P < 0.01). However, reduction of hematuria was
not significantly different between the 2-dose and




Comparison of parasito/ogica/ cure rate after 3 doses of metrifonate between children and adults showing the
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Number of subjects in parentheses.
After the transformation of egg count by log(x + I), differences between pre- and post-treatment were calculated and compared between adults
and children.
* Differences were statistically significant. (P < 0.05, Student's f-test.)
but the rate of reduction was higher in adults
than in children. When adults and children were
compared on the basis of intensity of infection
at higher bevels (Table 7), more drastic reductions
again were observed in adults than in children
(P < 0.05, Student's i-test).
Reduction of prevalence of gross hematuria in
relation to sex, age, and intensity of inftction
A total of 232 urine samples were analyzed,
with the results shown in Table 8. The rate of
reduction in frequency of bematuria did not dif
fer by sex, age, or intensity of infection.
DISCUSSION
The therapeutic efficacy of metrifonate has been
reported by many researchers.2'@â€•2 However,
most of the reports have dealt exclusively with
children as subjects. This study was designed to
determine the therapeutic effect of metrifonate
at the community level. A marked reduction in
infection intensity and prevalence of gross he
maturia was observed. Although our study
showed only a modest cure rate, the results con
firm that selective mass chemotherapy with me
trifonate is an effective control strategy for mor
bidity due to urinary schistosomiasis.
Infection in children was less responsive to
metrifonate than in adults. Lower cure rate and
smaller reduction in egg output ofchibdren could
be due to the age of the subjects or to higher
intensity of infection. It is recognized that cure
rate is greatly affected by pretreatment egg
count,7'8' 13and also that age plays an important
role in the effectiveness of many drugs.'4
The rate of improvement from gross hema
turia was similar in all ages and in all but the
lowest class of infection intensity, in which prev
alence of hematuria was too low to draw a con
clusion. The results suggest that morbidity in an
entire community decreases homogeneously af
ter treatment while intensity of infection remains
TABLE 8
Reduction of prevalence of gross hematuria in patients receiving 3 doses of met rifonate by sex, age, and intensity
of infrction
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heterogeneous. The improvement of gross he
maturia using the 3-dose regimen is comparable
to results obtained using praziquante! in Lake
Volta, Ghana.'5
Efficacy of metrifonate has been reported to
be dose-dependent.7 This was confirmed by the
cure rate and reduction in intensity of infection
in our study. The cure rate by 3 doses in our
study is lower than that reported from other en
demic areas,89 which might be due to either vari
ances in infection intensity or to a difference in
schistosome susceptibility to metrifonate, as has
been suggested by Wilkins and Moore.â€•
A single dose of metrifonate showed compar
atively marked reduction in urine egg count. 0. @2
Three out of 6 subjects with hematuria at pre
treatment were negative and without red urine
at post-treatment examination after a single dose.
This indicates a promising effect of single-dose
metrifonate on morbidity due to S. haemato
bium infection. Two doses of metrifonate re
duced prevalence of gross hematuria similarly to
3 doses; therefore a 2-dose regimen is recom
mended and expected to increase compliance, as
it did in our study by 20%.
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